As of 2024-12-12, the EV/EBITDA ratio of Novavax Inc (NVAX) is -5.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Novavax's latest enterprise value is 1,072.47 mil USD. Novavax's TTM EBITDA according to its financial statements is -204.92 mil USD. Dividing these 2 quantities gives us the above Novavax EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 17.7x | 15.7x |
| Forward P/E multiples | 18.6x - 33.5x | 25.9x |
| Fair Price | (21.70) - (20.57) | (24.49) |
| Upside | -346.0% - -333.2% | -377.6% |
| Date | EV/EBITDA |
| 2024-12-06 | -5.33 |
| 2024-12-05 | -4.83 |
| 2024-12-04 | -4.83 |
| 2024-12-03 | -4.91 |
| 2024-12-02 | -5.19 |
| 2024-11-29 | -5.16 |
| 2024-11-27 | -5.08 |
| 2024-11-26 | -5.18 |
| 2024-11-25 | -5.62 |
| 2024-11-22 | -4.96 |
| 2024-11-21 | -4.62 |
| 2024-11-20 | -4.64 |
| 2024-11-19 | -4.59 |
| 2024-11-18 | -4.46 |
| 2024-11-15 | -4.06 |
| 2024-11-14 | -3.98 |
| 2024-11-13 | -4.41 |
| 2024-11-12 | -4.95 |
| 2024-11-11 | -5.38 |
| 2024-11-08 | -5.30 |
| 2024-11-07 | -5.51 |
| 2024-11-06 | -5.34 |
| 2024-11-05 | -5.72 |
| 2024-11-04 | -5.47 |
| 2024-11-01 | -5.65 |
| 2024-10-31 | -5.85 |
| 2024-10-30 | -6.03 |
| 2024-10-29 | -6.21 |
| 2024-10-28 | -6.35 |
| 2024-10-25 | -5.96 |
| 2024-10-24 | -6.09 |
| 2024-10-23 | -6.16 |
| 2024-10-22 | -6.25 |
| 2024-10-21 | -6.27 |
| 2024-10-18 | -6.30 |
| 2024-10-17 | -6.43 |
| 2024-10-16 | -6.27 |
| 2024-10-15 | -8.19 |
| 2024-10-14 | -8.20 |
| 2024-10-11 | -8.13 |
| 2024-10-10 | -8.43 |
| 2024-10-09 | -8.25 |
| 2024-10-08 | -8.53 |
| 2024-10-07 | -8.52 |
| 2024-10-04 | -8.98 |
| 2024-10-03 | -9.61 |
| 2024-10-02 | -9.81 |
| 2024-10-01 | -7.97 |
| 2024-09-30 | -8.21 |
| 2024-09-27 | -8.74 |